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Abstract
Objective: To find out whether a high number of auto-antibodies can increase the probability of a ‘‘good-EULAR response’’
and to identify the possible biomarkers of response in seropositive rheumatoid arthritis (RA) patients undergoing the B cell
depletion therapy (BCDT).
Patients and Methods: One hundred and thirty-eight patients with long standing RA (LSRA), 75% non or poorly responsive
to one or more TNFa blockers, all seropositive for at least one autoantibody (AAB) (RF-IgM, RF-IgA, RF-IgG, anti-MCV, ACPA-
IgG, ACPA-IgA, ACPA-IgM) received one full course of BCDT. The major outcomes (moderate or good-EULAR response) were
assessed after 6 months of therapy. The IL6 and BAFF levels were also determined.
Results: At a 6-month follow-up, 33 (23.9%) of the RA patients achieved a good EULAR response. Having up to 5-AABs
positivity increased the chances for treatment response. After a logistic regression analysis, however, only 4 baseline factors
arose as associated with a good-EULAR response: no steroid therapy (OR = 6.25), a lymphocyte count,1875/uL (OR = 10.74),
a RF-IgG level .52.1 IU/ml (OR= 8.37) and BAFF levels ,1011 pg/ml (OR= 7.38). When all the AABs, except for RF-IgM and
ACPA-IgG, were left in the analysis, the two final predictors were no-steroid therapy and low lymphocyte count.
Discussion: The number of AABs increased the chances of being a ‘‘good-EULAR’’ responder. The only predictors, however,
at the baseline of a good response in this seropositive cohort of RA patients were 2 simple variables – no steroids and
lymphocyte count – and two laboratory assays – IgG-RF and BAFF.
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Introduction
In rheumatoid arthritis (RA), the inflammation in the synovial
tissue is an acute-chronic process that is caused by several
inflammatory cells and cytokines [1]. Among the cellular players,
the B cells are present in the synovial tissue of several types of
arthritides where they act as an antigen presenting cells and
producing cytokines and autoantibodies, some of which have been
linked to a poor prognosis [2,3]. Thus, we have been led to
consider the B cells as a definite target in RA, especially the RA
subtype with the poorest prognosis, i.e. the rheumatoid factor (RF)
positive patients. The BCDT has become a possible second choice
due to poor response to TNFa blockers in RA patients [4–6]. Data
from clinical trials regarding BCDT indicate that patients positive
for IgM rheumatoid factor (IgM-RF) and/or for anti-citrullinated
peptide autoantibodies (ACPA) are those achieving the best
clinical results in terms of ACR or good EULAR response [7,8].
According to the data, the best candidate for the BCDT has been
generally identified as the patient partially or fully refractory to
a TNFa blocker, the RF or the ACPA positive. Therefore,
seropositivity appears to be the best available biomarker in clinical
practice for defining the best patient target for the treatment
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[9,10]. Whether the IgM-RF or the ACPA, or both, are the best
available biomarkers associated to treatment response still remains
to be demonstrated.
Since not all seropositive patients obtain clinical benefits from
the BCDT, one unfulfilled need is the identification of the ideal
target among the autoantibody-positive patients, but no data are
available regarding which parameters or variables can best identify
the subject that benefits the most or the least among the
seropositive RA patients. Furthermore, it is unknown whether
multiple positivity of autoantibodies can confer a higher proba-
bility of response in RA.
In this study, we addressed the issue of which disease-specific
characteristics, as well as biologic parameters, could be predictive
factors of response to the BCDT in still active RA patients, in
a cohort of patients all seropositive for at least one autoantibody
(RF-IgG, IgA, or IgM, or ACPA-IgG, IgA or IgM or antibodies
directed against a mutated citrullinated vimentin-anti-MCV). The
primary aim was to define whether the higher the number of
AABs, the higher would have been the chance of selecting the best
responder. The secondary aim was to define biomarkers of good-
EULAR response and possibly to obtain thresholds of each factor
directly involved in the BCDT response that would be applicable
in clinical practice.
Patients and Methods
Ethical statement
The ethical approval for the study was obtained from the
Ethical Committee of the Catholic University of the Sacred Heart.
All subjects gave their written informed consent.
Patients
In this open-label retrospective, non-comparative, non-inter-
ventional study, RA patients from six Italian centers (two in Rome,
Pavia, Florence, Verona, Milan), starting treatment with rituximab
for the first time, were followed since 2006; thus, this is
a retrospective observational study. Among the recruited patients,
138 AAB positive patients were included in the current in-
vestigation (see below). All patients had been diagnosed with RA
following the American College of Rheumatology criteria [11] and
admitted to the study because of an incomplete and/or poor
response to conventional combination-DMARDs (Methotrexate-
MTX, Leflunomide-LFN, Sulphasalazine-SSZ, Chloroquine-
CHL) and/or TNFa blockers (one or more). They were still
active after six months of combination therapy as either DMARDs
or MTX+TNFa blockers. Steroids were allowed, but only to those
patients who took the dosage of 5–7.5 mg/day and the patients
that did not change the dosage over the study period were
included in the analysis. The BCDT along with MTX (dose range:
10–25 mg/week according to tolerability) was used in 35 patients
as the first choice due to comorbidities that excluded the anti-
TNFa therapy. Eighteen patients, having had previous toxicities
with MTX or other DMARDs, received the BCDT only. All
patients received the BCDT (Rituximab 1 g twice, one infusion
every two weeks). At baseline and every 3 months, demographic,
clinical, including previous TNFa blocker therapies and current
therapy with glucocorticoids, immunological and laboratory data,
the Health Assessment Questionnaire (HAQ) and the disease
activity score (DAS) were recorded. Clinical assessment using the
DAS score was performed every three months of treatment. The
EULAR response criteria based on the DAS were used to assess
the disease activity during the follow-up. Good responders were
defined subjects with a .1.2 improvement in the DAS from
baseline and with a DAS attained during follow-up of #2.4. Non-
responders were patients with an improvement of #0.6 or patients
with an improvement of .0.6 but #1.2 and a DAS attained
during follow-up of .3.7. Patients with a DAS #3.7 and an
improvement of .0.6 were classified as moderate responders, that
obviously include the good responders. [12].
Moreover, CD19 count, erythrocyte sedimentation rate (ESR)
and C-reactive protein (CRP) and routine haematological and
serum chemistry determinations were performed every three
months. Serum immunoglobulin levels (IgG, IgA and IgM) were
assessed by enzyme-linked immunosorbent assay (ELISA).
Detection of Autoantibodies
IgA, IgG and IgM ACPA isotypes were measured using an EliA
method on the ImmunoCAP 250 instrument (Phadia, Freiburg,
Germany), with positive anti-CCP defined as $7 U/ml for IgG,
$2.2 U/ml for IgA and $100 U/ml for IgM, as suggested by the
manufacturer. The anti-MCV (anti-modified citrullinated vimen-
tin) antibodies and the RF (IgG, IgA and IgM isotypes) were
measured by ELISA (Orgentec Diagnostika GmbH, Mainz,
Germany) and considered positive above a cut-off value of
20 U/ml as suggested by the manufacturer. The ACPAs and
RFs were determined using plasma samples that had been stored.
All the patients admitted to the study were positive for at least one
autoantibody.
Inflammatory biomarkers
Serum levels of IL-6 and BAFF were measured by ELISA (R&D
Systems, UK). The sensitivity of the test was of 0.7 pg/ml for IL6
and 3.38 pg/ml for BAFF.
Statistical analysis
A statistical analysis was performed using SPSS statistical
software (SPSS for Macintosh, version 15 PSS, Chicago, IL, USA)
and the MedCalc 8.0 package (MedCalc Software, Mariakerke,
Belgium). Data were recorded as mean and Standard Deviation
(SD) or number and percentage. In order to calculate the sample
size, the following parameters were used: power 80%; level of
confidence 95%; the frequency of ‘‘good response’’ to the BCDT
after 6 months of treatment in the RA patients was 25.0% (based
on the mean value of the European studies) [10] and the estimated
frequency of 50.0%. The sample size calculation was performed
using the formula for binary data. The sample size was estimated
to be 130 RA cases.
A receiving operating curve (ROC) analysis [13] of the
continuous parameters related to the ‘‘good EULAR response to
the BCDT after the sixth month of follow-up’’ or ‘‘moderate
EULAR response to the BCDT in the RA patients were
performed in order to obtain relevant thresholds allowing the
prediction of response to therapy at the individual level.
The nonparametric ROC plot uses all of the data, makes no
parametric assumption and provides unbiased estimates of
sensitivity and specificity. The calculation of area under the curve
(AUC) provides a convenient single number. AUC values $0.550
or #0.450 were considered to be discriminative and
0.45,AUC,0.55 to be nondiscriminative. The optimal cutoff
point was determined to yield the maximum corresponding
sensitivity and specificity.
The following potential predictors of response to the BCDT
therapy at a 6-month follow-up were evaluated using the x2 test:
gender; previous anti-TNF therapy; current steroid therapy and
current DMARDs therapy; seropositivity for anti-MCV, ACPA
(IgG, IgA or IgM), RF (IgG, IgA or IgM); baseline DAS score;
baseline HAQ; baseline ESR, CRP, IL6 and BAFF levels and
baseline lymphocytes count.
BCDT in AAB+ RA: Predictors of Good Response
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Two logistic multivariate regression models with stepwise
backward-wald elimination to study the associations respect to
two outcomes (good or moderate EULAR response) were used.
The covariates included in the models had a p#0.10 in the
univariate analysis. The probability of stepwise to entry was settled
at 0.05 and to remove was settled at 0.10. The goodness of fit of
the models was performed using the Hosmer-Lemeshow test.
Statistical significance was defined as p,0.05.
Results
Demographic, Clinical and Immunological Characteristics
of the RA Patients at the baseline
The clinical, immunological and demographic characteristics at
the baseline of the 138 RA patients are shown in Table 1. All
patients had a moderate-active disease (DAS.2.4) as shown by the
high DAS (4.561.2) and HAQ (1.6760.75) scores. More
specifically, 75% had a DAS score .3.7. In the RA cohort,
25.4% were TNF blockers naı¨ve while 41.7%, 46.6% and 11.7%
of the patients had failed one, two or three TNF inhibitors. One
hundred and twenty-two patients were treated with MTX (range
10–20 mg), with the dosage remaining stable during the follow-up
period. Overall 110 patients were receiving concomitant oral low-
dose prednisone (range 5–7.5 mg/day). Eighteen of these patients
were receiving only small doses of prednisone at the moment they
underwent the BCDT, no MTX nor other DMARDs.
Autoantibody Pattern in RA Patients Treated with BCDT
All the RA patients gave sera and were tested for all the
autoantibody positivity, using the cut-off value recommended by
the manufacturers. Among patients, 89 (64.5%) were RF-IgM
positive, 116 (84.7%) were ACPA-IgG positive, 123 (89.1%) were
positive for anti-MCV antibodies of which 113 (81.9%) were also
anti-CCP (IgG) positive and 11 (8%) were only RF positive (IgG
and/or IgM and/or IgA) (Table S1).
EULAR Clinical Response after 6 Months of BCDT
Treatment in Seropositive RA Patients
At end of the 6-month follow-up, 33 of the 138 (23.9%) RA
patients achieved a good EULAR response while a moderate-
EULAR response was reached in 71 (51.4%) patients and 34
(24.7%) RA patients were poor responders. Fourteen (10.1%) RA
patients were in EULAR-remission at the end of the 6-month
period.
Considering the cut-off levels recommended by the manufac-
turers for each autoantibody positivity, no association was seen
between the AAB pattern and the response to the BCDT therapy.
(Table S1). The RA patients reaching a good-EULAR response to
BCDT at the sixth month follow-up had a significantly different
distribution of the number of AAB positivity compared to the
patients with a poor-EULAR response (x2 test = 16.69, p = 0.01).
In particular, the RA patients reaching the good-EULAR response
had 3 to 5 AAB positivity in much higher percentage (84.8%) that
poor-EULAR responders (46.7%, p,0.001). Moreover, the cut-off
number resulted from the ROC curve analysis
(AUC = 0.53660.051) for the positivity of AAB was 5 (Table 2
and Figure S1).
As shown in Table S2, the variables related to response to the
BCDT therapy at the sixth month follow-up in univariate analysis
were no current steroid therapy (p,0.001), a DAS score of less
than 3.7 and a HAQ score less than 1.5 (p = 0.01), a baseline
lymphocyte count ,1875/ml (p = 0.002), a CRP,5 mg/l
(p = 0.01), BAFF,1011 pg/ml (p = 0.04) and IL6,15 pg/ml
(p = 0.01) levels and a baseline anti-MCV.36.5 U/ml (p = 0.04)
and RF-IgG.52.1 U/ml (p = 0.01) AAB levels.
In the logistic regression analysis, the best independent
predictors of ‘‘good EULAR response to the BCDT after the
sixth month follow-up’’ in the RA patients were baseline
lymphocyte count ,1875/uL (OR (95% CI): 10.74 (2.21–
52.13)), RF IgG levels .52.1 IU/ml (OR (95% CI): 8.37 (1.34–
52.14)), plasma BAFF levels ,1011 pg/ml (OR (95% CI): 7.38
(1.24–43.76)) and no-current steroid therapy (OR (95% CI): 6.25
(1.28–33.33)) (Table 3). The IgG, IgA and IgM levels, as well as
the titres of the AABs, resulted not significant.
Considering the number of autoantibody positivity instead of
dichotomous single AAB values, we have again found that the best
Table 1. Baseline demographic, clinical and immunological
characteristics of RA patients included in the study.
RA patients
N 138
Gender: Female, n. (%) 114 (82.6)
Age (years) 61.3611.5
Disease duration (years) 13.0610.6
Anti-TNF naı¨ve, n (%) 35 (25.4)
Previous anti-TNF agents used
N=1, n (%) 43 (41.7)
N=2, n (%) 48 (46.6)
N=3, n (%) 12 (11.7)
Current DMARDs therapy, n (%) 122 (88.4)
Current steroid therapy, n (%) 110 (80.3)
Tender joint count (n) 18.8612.6
Swollen joint count (n) 10.967.6
CRP (mg/L) 21.6622.6
ESR (mm/1st hour) 48.5625.4
DAS 4.661.2
HAQ 1.6660.74
Anti-CCP IgG (U/ml) 190.26127.0 (151.0)*
Anti-CCP IgG $7.0 U/ml, n (%) 116/137 (84.7)
Anti-CCP IgM (U/ml) 371.16281.1 (303.0)*
Anti-CCP IgM $100 U/ml, n (%) 33/137 (24.1)
Anti-CCP IgA (U/ml) 20.4624.1 (7.5)*
Anti-CCP IgA $2.2 U/ml, n (%) 66/137 (48.2)
RF-IgG (U/ml) 174.06216.7 (102.3)*
RF-IgG $20U/ml, n (%) 111/137 (81.0)
RF-IgM (U/ml) 156.36158.3 (89.4)*
RF-IgM $20U/ml, n (%) 89 (64.5)
RF-IgA (U/ml) 159.56176.0 (90.1)*
RF-IgA $20U/ml, n (%) 74 (53.6)
Anti-MCV (U/ml) 447.76465.7 (216.3)*
Anti-MCV $20U/ml, n (%) 123 (89.1)
Values are mean 6 sd unless otherwise indicated. *values are reported as mean
6 sd (median).
RA = rheumatoid arthritis; TNF = tumor necrosis factor; DMARDs = disease
modified anti-rheumatic drugs; CRP= C-reactive protein; ESR = erythrocyte
sedimentation rate; DAS = disease activity score; HAQ=Health Assessment
Questionnaire; CCP = cyclic citrullinated protein; RF = rheumatoid factor; MCV =
modified citrullinated vimentin.
doi:10.1371/journal.pone.0040362.t001
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independent predictors of ‘‘good EULAR response to the BCDT
after the sixth month FU’’ in RA patients were the baseline low
lymphocyte count ,1875/uL (OR (95% CI): 7.45 (1.96–28.27)),
plasma BAFF levels ,1011 pg/ml (OR (95% CI): 7.16 (1.43–
35.74)) and no current steroid therapy (OR (95% CI): 11.23 (2.56–
50.00)). In the last step of the model, the number of AAB positive
up to 5 remained, even though it did not reach statistical
significance (OR (95% CI): 4.50 (0.95–26.21)).
Using the model shown in Table 3 for the outcome, but without
the contribution of the IgG-RF parameter, we have shown that the
best independent predictors of ‘‘good EULAR response to the
BCDT after the sixth month FU’’ in the RA patients were
a baseline lymphocyte count of ,1875/uL (OR (95% CI): 7.92
(2.08–30.23)), plasma BAFF levels ,1011 pg/ml (OR (95% CI):
7.58 (1.48–38.90)) and no current steroid therapy (OR (95% CI):
11.11 (2.50–50.00)). The use of the same model reported in
Table 3, together with the removal of all the AAB, except for the
IgM-RF and ACPA-IgG in the stepwise multivariate regression
analysis revealed both a low lymphocyte count and no-steroids as
the best predictors.
After considering the contribution of the 4 predictive param-
eters, lymphocyte count, the BAFF levels, no current steroid
therapy, IgG-RF autoantibody level, we observed that a higher
percentage of patients fulfilling all the parameters obtained a good-
response compared to patients satisfying none or only one
parameter (54.5% vs 20.8%, p = 0.046). (Figure 1).
In order to see whether the ‘‘good-EULAR response’’ was a too
strict clinical endpoint and then it could identify too selective
biomarkers, we analyzed all the data in light of the ‘‘moderate
EULAR response’’. The variables emerging from the univariate
analysis showed that a lymphocyte count,1546 mL and no-
current steroid therapy again arose as the most significant among
all the variables (Table S3).
At the logistic regression analysis, the baseline lymphocyte count
,1546 mL (OR (95% CI): 278.62 (8.71–8911.03)), plasma BAFF
levels ,1002 pg/ml (OR (95% CI): 25.93 (1.95–344.19)) and no-
current steroid therapy (OR (95% CI): 20.0 (1.00–500.00))
emerged again as significant independent factors among the best
independent predictors of ‘‘moderate EULAR response’’ to the
BCDT after the 6-month FU (Table 4). In addition a low HAQ
Table 2. ROC curve analysis: Area Under the Curve (AUC) for considered biomarkers in good or moderate-EULAR responders
compared to poor-EULAR responder RA patients.
Variable Good-EULAR response Moderate-EULAR response*
AUC Std.Errora pb AUC Std.Errora pb
HAQ 0.639 0.068 0.05 0.242 0.061 0.001
Lymphocytes (u/ul) 0.655 0.072 0.03 0.297 0.067 0.01
ESR (mm/1st hr) 0.601 0.072 0.16 0.383 0.073 0.12
CRP (mg/l) 0.623 0.072 0.09 0.377 0.072 0.11
BAFF (pg/ml) 0.633 0.066 0.09 0.402 0.076 0.20
IL6 (pg/ml) 0.621 0.069 0.07 0.380 0.075 0.12
Anti-CCP IgG (U/ml) 0.486 0.061 0.61 0.381 0.077 0.12
Anti-CCP IgM (U/ml) 0.482 0.064 0.78 0.515 0.078 0.84
Anti-CCP IgA (U/ml) 0.518 0.062 0.78 0.437 0.078 0.41
RF-IgG (U/ml) 0.379 0.062 0.07 0.546 0.077 0.55
RF-IgM (U/ml) 0.439 0.065 0.36 0.544 0.078 0.56
RF-IgA (U/ml) 0.555 0.067 0.50 0.451 0.076 0.52
Anti-MCV (U/ml) 0.434 0.060 0.49 0.418 0.078 0.28
AB positivity 0.535 0.051 0.54 0.456 0.079 0.56
aUnder the nonparametric assumption; bNull hypothesis: true area = 0.5.
*Subjects included in the group ‘‘moderate-EULAR response’’ were patients that have reached good or moderate response. CRP= C-reactive protein; ESR = erythrocyte
sedimentation rate; HAQ=Health Assessment Questionnaire; BAFF = B cell activating factor; IL = interleukin; CCP = cyclic citrullinated protein; RF = rheumatoid factor;
MCV= modified citrullinated vimentin; AB = autoantibodies.
doi:10.1371/journal.pone.0040362.t002
Table 3. Logistic regression model t predicting 6th month
good- EULAR response to BCDT in RA patients.
Variables OR (95% CIs)
Current steroid therapy yes = 1 0.16 (0.03–0.78)
DAS, ,3.7 = 1 0.88 (0.15–5.06)
HAQ, ,1.5 = 1 2.24 (0.49–10.18)
Lymphocytes, ,1875/ul = 1 10.74 (2.21–52.13)
ESR, ,30mm/1st hr = 1 5.55 (0.93–29.00)
CRP, ,5mg/l = 1 2.17 (0.21–21.95)
BAFF, ,1011 pg/ml = 1 7.38 (1.24–43.76)
IL6, ,15 pg/ml = 1 3.59 (0.78–16.40)
IgG-RF, .52.1U/ml = 1 8.37 (1.34–52.14)
IgA-RF, ,37U/ml = 1 3.34 (0.68–16.45)
Anti-MCV, .36.5U/ml = 1 6.17 (0.63–60.07)
Hosmer and Lemeshow test p = 0.95
The cut-off values for continuous variables related to the ‘‘good EULAR
response to BCDT after 6th months FU’’ were obtained with ROC curves
analysis. OR = odds ratio; 95%CI = 95% confidence interval; CRP =C-reactive
protein; ESR = erythrocyte sedimentation rate; DAS= disease activity score;
HAQ=Health Assessment Questionnaire; CCP = cyclic citrullinated protein; RF =
rheumatoid factor; MCV = modified citrullinated vimentin. Boldface type
indicates that P value is less than 0.05.
doi:10.1371/journal.pone.0040362.t003
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and a positive anti-MCV arose as co-factors predicting a moderate
response.
Discussion
Optimizing therapy in RA becomes more and more important
given the huge cost of all biologics once RA does not respond to
methotrexate [14] or to combination therapy with conventional
DMARDs [15,16]. On the one hand, a way to optimize the
therapy is the choice of biologics on the basis of the best
responders or, on the other hand, of the worst responder. Among
the biologics, the BCDT with rituximab has become a standard of
therapy in poor responder patients to TNFa blockers. Some
investigators suggest using it after the first TNFa blocker failure
[17,18]. Thus, identifying the best possible responder is of
fundamental importance. In fact, a delay of at least 4 to 6 months
is needed before drawing an initial conclusion to the response to
the BCDT and 6 months can cause structural damage if the
disease activity does not decrease. In the case of a poor clinical
control this might lead to sustained structural damage [19].
No real clues have been detected from tissues. In some studies,
an attempt was made to use the immunohistological analysis of the
synovial membrane as a way to identify the best response. No
baseline data emerged as possible response biomarkers, but the
better the depletion over time the better the clinical results.
Moreover, the study from Teng et al demonstrated that a low
disease activity following rituximab treatment was associated with
reduced infiltration of early plasma cells in synovium, suggesting
that the reduction of disease activity by BCDT in patients with RA
could be explained by the presence of VD79a+ plasma cells in the
synovium [20–22].
Figure 1. Percentage of good and moderate EULAR response rate (%) in RA patients after 6 months of RTX therapy. Patients were
grouped according to the number of fulfilled parameters (corticosteroids therapy, number of circulating lymphocytes ,1875/ml, plasma BAFF levels
,1011 pg/ml and RF-IgM .52.1 U/ml). Good response was reached in 20.8% of RA patients that fulfilled 0–1 parameter, in 29.2% of subjects that
fulfilled 2–3 parameters and in 54.5% of subjects that fulfilled 4 parameters (Fisher’s exact test between 4 parameters and 0–3 = 0.08). Moderate-
response was reached in 41.7% of RA patients that fulfilled 0–1 parameter, in 54.5% of subjects that fulfilled 2–3 parameters and in 72.7% of subjects
that fulfilled 4 parameters (x2 test = 3.02, df = 2; p= 0.22). *p= 0.046: percentage of good response in patients fulfilling 4 vs 0–1 parameters.
doi:10.1371/journal.pone.0040362.g001
Table 4. Logistic regression model to predicting 6th month
moderate EULAR response to BCDT in RA patients.
Variables OR (95% CI)
Current steroid therapy yes = 1 0.05 (0.002–0.98)
DAS, ,3.7 = 1 2.59 (0.32–20.92)
HAQ, ,1.0 = 1 48.33 (2.78–840.24)
Lymphocytes, ,1546/ul = 1 278.62 (8.71–8911.03)
ESR, ,60mm/1st hr = 1 5.38 (0.56–51.59)
CRP, ,5mg/l = 1 0.33 (0.01–9.48)
BAFF, ,1002 pg/ml = 1 25.93 (1.95–344.19)
IL6, ,20.2 pg/ml = 1 3.04 (0.32–28.79)
IgG-ACPA, ,273U/ml = 1 1.56 (0.02–117.97)
IgM-ACPA, ,158U/ml = 1 3.79 (0.05–276.59)
IgG-RF, .25.6U/ml = 1 0.81 (0.04–15.91)
IgM-RF, .38.6U/ml = 1 19.93 (2.21–180.22)
Anti-MCV, ,407.7U/ml = 1 56.29 (1.71–1847.17)
Hosmer and Lemeshow test p = 0.63
The cut-off values for continuous variables related to the ‘‘moderate-EULAR
response to BCDT after 6th months FU’’ were obtained with ROC curves
analysis. OR = odds ratio; 95%CI = 95% confidence interval; CRP =C-reactive
protein; ESR = erythrocyte sedimentation rate; DAS= disease activity score;
HAQ=Health Assessment Questionnaire; CCP = cyclic citrullinated protein; RF =
rheumatoid factor; MCV = modified citrullinated vimentin. Boldface type
indicates that P value is less than 0.05.
doi:10.1371/journal.pone.0040362.t004
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Trial data suggested that IgM-RF could be used to identify the
best target [23]. In the Serene trial, the analysis of predictors led to
identify all isotypes of RF as well as IgG-ACPA as possible
predictors of a good response [24]. Even preliminary data in
a retrospective cohort, from randomly chosen patients confirmed
RF as a possible biomarker [9]. On the other hand, another larger
observational cohort showed that ACPA-IgG were a better
biomarker of good-EULAR response than IgM-RF [10]. The
rationale that both AABs could be important was supported by the
French multicenter study carried out on 208 patients in which
21% reached a good-EULAR and 50% a partial-EULAR
response after BCDT therapy. It showed that the response was
associated with IgM-RF or ACPA or high IgG levels, thus
suggesting that the 3 variables could allow for the selection of the
best responder before treatment [25]. Note that 50% of the
seronegatives, either for ACPA-IgG or for IgM-RF, responded.
Moreover, in the French cohort the majority of the patients were
anti-TNF poor responders. Therefore, the biomarkers can only be
applied to the TNF-blockers poor responder patients. All data
derived from pooling seropositive and seronegative patients cannot
be applied to fully seropositive patients. But the data seem to
confirm that both AAB are crucial and the double seropositivity
could involve a higher risk.
In a small retrospective cohort, a BLyS single nucleotide
polymorphism (SNPs), which is generally associated with low levels
of the cytokine, appeared as a possible biomarker of moderate-
good response [25], but data have yet to be confirmed.
To answer some of the questions, we studied only the
seropositive RA patients. The selection of all seropositive patients
was made with the idea that, since seropositivity seems to be the
main driver, then the higher the positivity of the isoform of RF or
ACPA, the higher should have been the chance of selecting the
best responder. In our cohort, we observed that the higher the
number of AAB the higher the chance of getting a response to
BCDT. In addiction, we were able to identify, in the logistic
regression analysis, 4 parameters which are associated strictly to
a good-EULAR response. Two of these biomarkers are easily
identifiable at the baseline, i.e. a low lymphocyte count and no-
steroid therapy and two others are biological (high IgG-RF and
low BAFF plasma levels). Neither gender, nor previous therapies,
arose as predictors, even though we observed more than a 2-fold
higher chance of obtaining remission in patients not previously
treated with TNF- blockers.
As mentioned in the French cohort of patients with long-
standing RA, anti-CCP or RF-IgM positivity and serum levels of
IgG .1266 mg/dl (upper normal limit) arose as predictors of
EULAR response. The good-EULAR response was reached in
22% of the patients [25]. Considering the moderate response our
data confirm the importance of RF-IgM, and suggest that anti-
MCV (not ACPA) could be predictors. Therefore, we only
partially confirmed the results of this study in that we have not
found an association between levels of auto-antibodies and
EULAR response. We observed some relationship with a higher
number of AABs. In our cohort, patients having RF without anti-
CCP were very few, thus explaining why a possible additive effect
could hardly have been identified. Sellam’s study [26] did not
reveal any useful information from the free light chain assessment,
nor from BAFF levels. In our study the baseline lymphocyte count,
the plasma BAFF levels, along with no-corticosteroid therapy
arose as strong predictors of the response. On the other hand, Lai
et al observed that all AABs (RF of all isotypes as well as IgG-
ACPA) were associated with a placebo-corrected ACR50 re-
sponse, thus suggesting that being seropositive, irrespectively of the
AAB, led to higher clinical response [24].
Certainly, our cohort differs from the French one in that the
number of ACPA-IgG and IgM-RF was lower in our study. The
number of patients treated with steroids was a bit higher. The
number of TNF-blocker untreated patients was certainly higher in
our study than in the French cohort. Most importantly, all our
patients were seropositive for at least one AAB. In our view, our
results obtained in a cohort of previously treated, but all
seropositive RA patients shed more light on the scientific issue
and offer the opportunity to speculate on several biological
questions. First, not using steroids in patients with active disease
means no compartmentalization nor lymphocytolysis before using
the BCDT, a very significant consideration when dealing with
a drug (Rituximab) that acts, among several mechanisms, through
the lysis, a complement dependent, antibody dependent cellular
cytotoxicity of the B cells. Our findings also mean that patients
with low lymphocyte counts can have an intrinsically favorable
prognosis. Secondly, the presence of high IgG-RF and low levels of
BAFF suggest a specific autoimmune inflammatory milieu. IgG-
RF has long been considered the main driver of autoimmune
rheumatoid inflammation, since small size immune complexes
containing IgG-RF appear to be consistently and continuously
monocyte-activating, contributing to the accrued local production
of TNFa and IL1 [27]. The data confirm Edward’s original
hypothesis regarding the consistent role of IgG-RF in driving the
persistence of RA inflammation [28] and the demonstration is
that, by depleting the B cells, along with a clinical improvement,
a drop of IgG-RF occurs [29]. Thus, there is indirect evidence that
the BCDT could be one mechanism of progressive de-activation of
rheumatoid inflammation. The other interesting point observed in
our analysis is the predictive power of low plasma levels of BAFF at
the baseline. It is well recognized that BAFF plays a crucial role in
the development and survival of B cells [30]. We previously
observed that clinical improvement in early RA associated with
a drop in the BAFF plasma levels suggests that though not strictly
linked to disease activity, BAFF represents one of the molecules
that drives the persistence of rheumatoid inflammation [31]. Low
BAFF levels are associated to a lower B cell survival and thus,
likely allow a better biological effect of the BCDT. Of course, were
this the case, other strategies could be envisioned in order to have
lower levels of the BAFF, before initiating the BCDT in RA.
Certainly, the low BAFF as a prognostic factor of a good response
to BCDT raises a lot of interesting questions about how to
modulate the environment of RA synovial inflammation in order
to put into practice a personalized treatment and to reach
a sustained remission [32–34].
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